Document ID: chunk:federal_register_of_legislation:F2024C00214:reg:9:p1
Version: federal_register_of_legislation:F2024C00214
Segment Type: reg
Provision Reference: reg 9 (pt 1/4)
Character Range: 4940–8111

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting non-Hodgkin lymphoma or death from non-Hodgkin lymphoma with the circumstances of a person's relevant service:
(1)          having infection with human immunodeficiency virus at the time of the clinical onset of non-Hodgkin lymphoma;
(2)          undergoing solid organ, stem cell or bone marrow transplantation before the clinical onset of non-Hodgkin lymphoma;
(3)          having an autoimmune disease from the specified list of autoimmune diseases before the clinical onset of non-Hodgkin lymphoma;
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
(4)          being treated with a drug or a drug from a class of drugs from the specified list of systemic immunosuppressive drugs for a continuous period of at least three months before the clinical onset of non‑Hodgkin lymphoma, and where that exposure has ceased, the clinical onset of non-Hodgkin lymphoma has occurred within ten years of cessation;
            Note: specified list of systemic immunosuppressive drugs is defined in the Schedule 1 - Dictionary.
(5)          for Richter syndrome only, having chronic lymphoid leukaemia/small lymphocytic lymphoma at the time of the clinical onset of non‑Hodgkin lymphoma;
Note: Richter syndrome is defined in the Schedule 1 - Dictionary.
(6)          for adult T-cell leukaemia-lymphoma only, having infection with human T-cell lymphotropic virus type-1 at the time of the clinical onset of non-Hodgkin lymphoma;
(7)          for gastric lymphoma and splenic marginal zone lymphoma only, having infection with Helicobacter pylori at the time of the clinical onset of non-Hodgkin lymphoma;
(8)          having infection with Epstein-Barr virus before the clinical onset of non-Hodgkin lymphoma;
(9)          for primary effusion lymphoma and Kaposi's sarcoma herpesvirus-positive diffuse large B-cell lymphoma not otherwise specified only, having infection with Kaposi's sarcoma herpesvirus at the time of the clinical onset of non-Hodgkin lymphoma;
(10)      for small intestinal mucosa-associated lymphoid tissue lymphoma only, having infection with Campylobacter jejuni at the time of the clinical onset of non-Hodgkin lymphoma;
(11)      for ocular adnexal mucosa-associated lymphoid tissue lymphoma only, having infection with Chlamydia psittaci at the time of the clinical onset of non-Hodgkin lymphoma;
(12)      for cutaneous mucosa-associated lymphoid tissue lymphoma only, having infection with specified bacteria belonging to the Borrelia burgdorferi sensu lato complex at the time of the clinical onset of non‑Hodgkin lymphoma;
            Note: specified bacteria belonging to the Borrelia burgdorferi sensu lato complex is defined in the Schedule 1 - Dictionary.
(13)      having infection with hepatitis C virus at the time of the clinical onset of non-Hodgkin lymphoma;
(14)      having infection with hepatitis B virus at the time of the clinical onset of non-Hodgkin lymphoma;
(15)      for Burkitt lymphoma only, having infection